Annual and Interim Reports
Annual General Meeting
Conflict Minerals Disclosure
Quarterly Results and Presentations
WHO WE ARE
Areas of Focus
How We Operate
Charitable Access Program
Our R&D Strategy
Science & Innovation
Investigator Initiated Research (IIR)
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
Early Talent Programs
Work Life Balance
Learn more about our unwavering commitment to patients around the world with bleeding disorders
View our animated infographic about the journey for patients with a rare disease.
Shire's National Eye C.A.R.E. Survey examines dry eye disease and the impact of today's high-tech world.
Shire is the leading biotechnology company focused on serving people with rare diseases.
In the fight against rare disease, every day is an opportunity to win. At Shire, we'll never stop championing the fight.
Having von Willebrand disease (VWD) means your blood doesn’t clot properly due to a
deficiency or dysfunction of von Willebrand factor
Shire’s CEO, Flemming Ornskov, announces the close of the Shire-Baxalta combination.
Ophthalmics has been a passion and priority for Shire since 2014, and we have achieved substantial progress in this category.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.